Drug Profile
Insulin peglispro
Alternative Names: Basal insulin peglispro; BIL; LY-2605541; Pegylated insulin lisproLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 01 Mar 2016 Eli Lilly withdraws a phase III trial in Type-2 diabetes mellitus in India, Israel, South Africa and China (NCT02106364)
- 04 Dec 2015 Discontinued - Phase-I for Type-1 diabetes mellitus (Combination therapy) in Germany (SC)
- 04 Dec 2015 Discontinued - Phase-I for Type-1 diabetes mellitus in Austria and USA (IV)